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A B S T R A C T
Purpose
Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in
basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only
subtype without established targeted therapy.
Patients and Methods
In this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody
cetuximab (400 mg/m2 load then 250 mg/m2 per week intravenously [IV]) alone, with carboplatin
(area under the curve of 2, once per week IV) added after progression or as concomitant therapy
from the beginning. Response rate (RR) was the primary end point; others included time to
progression (TTP), overall survival (OS), and toxicity. Embedded correlative studies included
molecular subtyping on archival tissue. Fresh tumor tissue before and after 7 to 14 days of therapy
was used for microarray analyses exploring EGFR pathway activity and inhibition.
Results
In 102 patients with TNBC, RRs were 6% (two of 31) to cetuximab and 16% (four of 25) to
cetuximab plus carboplatin after progression. RR to those treated from the beginning with
cetuximab plus carboplatin was 17% (12 of 71); 31% of patients responded or had prolonged
disease stabilization. The cetuximab plus carboplatin regimen was well tolerated, but both TTP
and OS were short at 2.1 months (95% CI, 1.8 to 5.5 months) and 10.4 months (95% CI, 7.7
to 13.1 months), respectively. Of 73 patients with archival tissue for analysis, 74% had
basal-like molecular subtype. Sixteen patients had tumor biopsies before and 1 week after
therapy; genomic patterns of the EGFR pathway showed activation in 13 and inhibition by
therapy in five.
Conclusion
Despite strong preclinical data, combination cetuximab plus carboplatin in metastatic TNBC
produced responses in fewer than 20% of patients. EGFR pathway analysis showed that most
TNBCs involved activation. However, cetuximab blocked expression of the EGFR pathway in only
a minority, suggesting that most had alternate mechanisms for pathway activation.
J Clin Oncol 30:2615-2623. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Breast cancer is a heterogeneous disease composed of
several biologically distinct subtypes.1,2 One of these
subtypes—basal-like breast cancer—comprises ap-
proximately 15% of breast cancers3 and carries poor
prognosis.4-6 Basal-like breast cancer is of great inte-
rest, because it is typically hormone receptor and
human epidermal growth factor receptor 2 (HER2)
negative and comprises the majority of tumors that are
triple negative on clinical assays for estrogen receptor
(ER), progesterone receptor (PR), and HER2. Triple-
negative breast cancer (TNBC) is the only clinical sub-
set for which we have no known targeted therapy.
The epidermal growth factor receptor (EGFR) is
an intriguing target in basal-like breast cancer. It is
highly expressed in the basal cluster on cDNA arrays5;
approximatelyhalfofbasal-likecancers express EGFR
by immunohistochemistry,7 and basal-like cell lines
are dependent on the EGFR pathway for prolifera-
tion and are sensitive to EGFR inhibitors.8 We
hypothesized that EGFR inhibition would be suc-
cessful in basal-like breast cancer selected by use of
the triple-negative phenotype.
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In this multicenter randomized phase II study performed by
the Translational Breast Cancer Research Consortium, an aca-
demic medical center collaborative group, we examined response
and outcome to the anti-EGFR monoclonal antibody cetuximab
alone or with carboplatin in metastatic TNBC. Cetuximab had not
been tested in breast cancer, so one arm included single-agent
cetuximab with carboplatin added on progression, whereas the
other explored combination cetuximab plus carboplatin through-
out, a combination with high effectiveness in cell line– based pre-
clinical models.8 Recognizing that our ability to understand
sensitivity and resistance to targeted therapy is limited in clinical
trials, this study was designed around, and focused on, several a
priori planned analyses of correlative end points from archival
specimens as well as fresh tumor samples obtained before and after
initiation of therapy in women with accessible metastatic tumor.
These analyses included determining the proportion of TNBCs
that were basal like and examining EGFR-related signatures in
predicting response to therapy.
PATIENTS AND METHODS
Patients
Eligible women had metastatic breast cancer measurable by RECIST
criteria and negative for ER, PR, and HER2 (0 or 1 on immunohistochem-
istry and/or normal gene copy number by fluorescence in situ hybridization)
and were recruited from October 2005 to October 2007. Receptor status was
determined by institutional criteria; central review was not required. Partici-
pants were allowed up to three previous chemotherapy regimens (adjuvant or
metastatic), no previous EGFR inhibitor or platinum for metastatic disease,
Eastern Cooperative Oncology Group performance status  3, no significant
organ dysfunction, CNS metastasis if stable for at least 3 months, and life
expectancy of at least 6 months. All patients provided written informed con-
sent, and the study was approved by the institutional review board at each site.
Treatment
Patients were randomly assigned (in a ratio of one to one) to receive
cetuximab alone with carboplatin added on progression (arm one) or combi-
nation cetuximab plus carboplatin (arm two). Cetuximab was administered at
400 mg/m2 intravenous (IV) load followed by infusions at 250 mg/m2 once per
week, and carboplatin was administered at an AUC of 2 IV on days 1, 8, and 15
of each 28-day cycle. Growth factors were permitted. Baseline and cyclic
evaluations included history, physical examination, and serum chemistry and
hematology profiles. Patients were restaged using computed tomography or
magnetic resonance imaging every 8 weeks and were treated until objective
disease progression, unacceptable toxicity, or withdrawal of consent. Treat-
ment was allowed to be delayed for up to 4 weeks beyond planned resumption
of the next cycle.
Correlative Studies
Formalin-fixed paraffin-embedded blocks were obtained from archival
specimens, and intrinsic subtyping was performed using a quantitative real-
time polymerase chain reaction–based method and the PAM50 gene set.9
When feasible (and with written consent), two tumor core biopsies were
obtained before and after 7 to 14 days of treatment. Any recurrent site and any
time during that timeframe were permitted. Gene expression profiling was
performed using Agilent DNA microarrays (Agilent Technologies, Santa
Clara, CA).8 Microarray data were deposited in the Gene Expression Omnibus
(GSE23428). The microarray data and the same PAM50 algorithm applied for
the quantitative real-time polymerase chain reaction were used for frozen
tissue intrinsic subtyping.9 A centroid-based predictor was used for claudin-
low subtyping.10
EGFR pathway status was determined by previously published gene sets
representing the whole pathway (defined by genes induced after removal of
EGFR inhibition in a basal-like cell line model)8; subsequent modeling dem-
onstrated that EGFR cluster 2 was most related to EGFR pathway activation.
Activation was defined by a cutoff value of the log2 ratio 0.147, as previously
described.8 Two other signatures were also examined as predictors of clinical
benefit using analysis of variance significance testing, including an 11-gene
proliferation signature (BIRC5, CCNB1, CDC20, NUF2, CEP55, NDC80,
MKI67, PTTG1, RRM2, TYMS, UBE2C)11 and a KRAS-amplicon signature
conserved between human and mouse.12 Cytoscape schematic diagrams of the
EGFR pathway (gene colors representing relative expression) were derived by
combining 36 arrays unique to this study with 248 breast tissue sample arrays
previously described,8 and genes were median centered across all 284 samples.
Statistical analysis was performed in R Development Core Team 2008 (release
2.5.1; R Foundation for Statistical Computing, Vienna, Austria).
Blood samples for circulating tumor cells (CTCs) were obtained at study
entry, after 7 to 14 days of single-agent therapy, after 7 to 14 days of combina-
tion therapy, every 4 weeks during therapy, and at progression. CTCs from
whole blood were processed and enumerated using a previously described
method,13 with staining for EGFR (immunoglobulin G1, kappa light chain
mouse monoclonal produced in house by Veridex [North Raritan, NJ]) mea-
sured in the fourth channel. Any CTCs found in 7.5 cm3 whole blood were
considered positive.
Data Analysis and Interpretation
The primary end point of the study was response rate (RR) by RECIST
criteria. Tumor response was evaluated every 8 weeks by the investigator and
confirmed independently by investigators blinded to arm and not involved
with the study. A Simon optimal two-stage design14 with maximum sample
size of 41 allowed early discontinuation of single-agent cetuximab for futility
if  one of the first 21 patients responded (72% likelihood of early stopping if
true RR was null value of 5%; 6% likelihood of early stopping if true RR was
alternative value of 20%). For the combination arm, a maximum sample size
of 52 allowed futility stopping after 21 patients if  two patients responded
(37% likelihood of halting if true RR was null value of 15%; 3% likelihood of
early stopping if true RR was alternative of 30%). Constrained block random-
ization (block size 21 plus 21) kept the imbalance between the arms to four at
most.15 Because both arms included combination therapy, accrual overruns
were permitted during interim analysis. If arm one was halted, and arm two
was not, another futility analysis was planned after 31 more patients were
assigned to arm two. If  seven of 51 patients responded, the trial would stop.
Primary analysis was of the intent-to-treat population; preplanned analyses
included evaluable patients (who received 4 weeks and at least 50% of planned
treatment; however, clearly progressing patients were evaluable). Complete
response (CR), partial response (PR), or disease stabilization for at least 24
weeks was considered clinical benefit (CB). Secondary end points included
overall survival (OS; defined from treatment initiation to death as a result of
any cause and calculated according to the Kaplan-Meier method), time to
disease progression (TTP; defined from treatment initiation to documented
progression), and correlative end points. Data cutoff was September 30, 2009.
All patients were evaluable for safety. Adverse events were graded according to
the National Cancer Institute (NCI) Common Terminology Criteria for Ad-
verse Events (CTCAE), version 3.0. Patient allocation and treatment assign-
ment are detailed in the CONSORT diagram (Fig 1).
RESULTS
Patient demographics and tumor characteristics are listed in Table 1.
Of 102 patients enrolled, 97 (95%) had received prior chemotherapy
in the (neo)adjuvant or metastatic setting. Of 86 patients with prior
(neo)adjuvant chemotherapy, 84 (98%) had received an anthracy-
cline; 65 (76%) had also received a taxane. Most had received chemo-
therapy for metastatic disease; 55 (54%) were treated in the second- or
third-line setting. As expected with TNBC, 78 (76%) had visceral
involvement; the liver or lung was the dominant site in 54 patients
(53%). They were minimally symptomatic; 94% had Eastern Cooper-
ative Oncology Group performance status of 0 to 1.
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CTCs
CTCs were assessed in 95 patients; 70 (74%) had at least five CTCs
per 7.5 mL, and 82 (86%) had any CTCs. Presence of CTCs in a single
7.5-mL blood sample was associated with progression-free survival
(PFS), a trend at baseline (P  .07) and significantly so after 7 to 14
days of treatment (P  .002). EGFR-positive CTCs were present in 36
patients (44%), which did not predict RR or PFS.
Single-Agent Cetuximab
Two of 31 patients experienced PR (6%; 95% CI, 1% to 21%),
and one had durable stable disease (SD; CB, 10%; 95% CI, 2% to 26%;
Table 2), with a TTP of 1.4 months (95% CI, 1.1 to 1.8). Both patients
with responses were in at least the second-line setting. Patients re-
ceived a median of 6 weeks of therapy (range, 3 to 166 weeks); discon-
tinuation was primarily for disease progression (19 patients; 61%);
two patients (6%) discontinued because of toxicity. Those with CB
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Fig 1. CONSORT diagram.
Table 1. Patient Demographics and Tumor Characteristics (N  102)
Characteristic
Arm 1 (n  31) Arm 2 (n  71)





White 19 61 51 72
African American 11 36 17 24
American Indian 1 3 1 1
Asian 0 0 2 3
ECOG PS
0 17 55 37 52
1 14 45 28 39
2 0 0 4 6
Missing 0 0 2 3
Menopausal status
Postmenopause 21 68 56 79
Pre- or perimenopause 10 32 15 21
Dominant metastatic site
Lung 9 29 20 28
Liver 8 26 17 24
LN 4 13 14 20
Locoregional 5 16 10 14
Bone 1 3 4 6
Skin/soft tissue 3 10 5 7
Other 1 3 1 1
Prior chemotherapy 30 97 67 94
Adjuvant/neoadjuvant 26 84 60 85
Metastatic 21 68 34 48
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; LN, lymph node.











C Only C  Cb† C  Cb
Basal-Like
Tumors‡
No. % No. % No. % No. %
CR 0 0 0 0 1 1 1 2
PR 2 6 4 16 11 16 7 14
SD 3 10 7 28 15 21 8 16
 6 months 1 3 3 12 10 14 7 14
PD 26 84 12 48 38 54 32 63
NE 0 0 2 8 6 8 3 6
Abbreviations: C, cetuximab; Cb, carboplatin; CR, complete response; NE,
nonevaluable; PD, progressive disease; PR, partial response; SD, stable
disease.
Combined Arms 1B and 2.
†After progression while receiving C.
‡Limited to those with confirmed basal-like disease by quantitative real-
time polymerase chain reaction–based intrinsic subtype assay.
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respectively. Arm one was closed after 31 patients, based on early
stopping rules for futility.
Cetuximab Plus Carboplatin
Of 71 patients treated in arm two (cetuximab plus carboplatin),
one experienced CR and 11 experienced PR, for an overall RR of 17%
(95% CI, 9% to 28%; Table 2). Ten had prolonged SD (CB, 31%; 95%
CI, 21% to 43%). The patients treated with combination cetuximab
plus carboplatin in arm one after progression while receiving single-
agent cetuximab had similar results (RR, 16%; CB, 28%). Response
was unrelated to line of therapy: five of 37 patients treated in first line
responded, and seven of 34 patients treated in second or third line
responded. Patients received a median of 8 weeks (range, 1 to 119
weeks) of combination cetuximab plus carboplatin; discontinuation
was because of progression in 55 patients (79%) and toxicity in
nine (13%).
TTP was 2.1 months (95% CI, 1.8 to 5.5) for those in arm two
(combination therapy from the beginning). It was 2.6 months (95%
CI, 1.8 to 4.7) for those receiving combination therapy after progres-
sion on single agent (Fig 2A).
Heterogeneity in response and outcomes after progression on
single-agent cetuximab was substantial. Two of 31 patients in the
single-agent arm and five of 71 in the combination arm rapidly pro-
gressed within 4 weeks of limiting drug exposure. Interestingly, four of
the five patients experiencing rapid progression while receiving com-
bination therapy were first-line patients. Conversely, as also seen in
another EGFR inhibitor trial,16 we saw long-term responses of  1
year in two patients receiving single-agent cetuximab (one ongoing
over 3 years) and two receiving combination therapy (one ongoing
nearly 2.5 years).
Survival
At a median follow-up of 26 months, 30 of 31 patients in arm
one had progressed through single-agent cetuximab administra-
tion, and 26 had died. In arm two, 55 of 71 patients had progressed,
and 59 had died. Median OS was 7.5 months (95% CI, 5.0 to 11.6)
for arm one and 10.4 months (95% CI, 7.7 to 13.1) for arm 2
(Fig 2B).
Toxicity
Single-agent toxicity was mild and, as expected, included rash,
fatigue, and infusion reactions. Adverse effects seen in at least 10% of
patients receiving cetuximab plus carboplatin included rash, fatigue,
and nausea. Grades 3 to 4 adverse events were uncommon and in-
cluded rash, fatigue, neutropenia, nausea, and hypersensitivity reac-
tions. A more detailed description of toxicity can be found in
Appendix Table A1 (online only). Both patients with grade 4 infusion
reactions came from the geographic region previously associated with
cetuximab hypersensitivity.17
Intrinsic Subtyping and Drug Effects on the
EGFR Pathway
Formalin-fixed paraffin-embedded archival tumor was avail-
able from 73 patients: 54 patients (74%) had basal-like, five (7%)
had HER2-enriched, four (5%) had luminal A, one (1%) had
luminal B, and nine (12%) had normal-like tumors. The very
long-term (166 weeks) responder to single-agent therapy had lu-
minal A TNBC.
We obtained fresh metastatic tumor from 18 patients. Two
were only able to be biopsied pretreatment, but 16 provided serial
biopsies before and after treatment for gene expression microarray
analysis: 11 (61%) had basal-like, four (22%) had claudin-low (a
subtype not represented in the PAM50 assay), one (5%) had
HER2-enriched, and two (11%) had normal-like tumors. In 14 of
16 serial biopsies, subtype stayed the same. One basal-like tumor
and one normal-like tumor changed to claudin low; this subtype
represented six (38%) of the post-treatment samples. In 13 (81%),
EGFR was expressed, and the pathway activated, allowing assess-
ment of inhibition with treatment (Figs 3A and 3B). Five (38%)
had at least 20% decrease in EGFR signature expression with treat-
ment (Fig 4A; Appendix Table A2, online only): one PR (with 
100% change based on comparison to reference [much higher
before and much lower after therapy]), two SD, and two progres-
sive disease. All eight tumors with persistent EGFR pathway acti-
vation after treatment had progressive disease.
Although EGFR as a single marker was unassociated with CB,
several other markers were associated with PR or SD (Figs 4B and 4C;
Arm 1: cetuximab





























































































































4 8 12 16 20 24 28 32 36 40
Fig 2. (A) Time to progression (TTP) with cetuximab alone and combination
cetuximab plus carboplatin. (B) Overall survival (OS) in patients treated initially
with cetuximab alone followed by cetuximab plus carboplatin on progression
(blue line) and in patients treated with cetuximab plus carboplatin from the beginning
(yellow line). 95% confidence limits shaded; crosses indicate censored data.
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Figs 5A to 5F), including low expression of the EGFR activation cluster
in the samples obtained 7 to 14 days after beginning therapy. Low
proliferation signature (P  .001) was associated with CB (P  .001).
KRAS expression itself was unrelated; however, low KRAS-amplicon
expression in post-treatment specimens was associated with response
(P  .04). Because KRAS mutations are uncommon in breast can-
cer,8,12 unlike in colon cancer, these variations were likely the result of
nonmutational influences. Previous studies have implicated phospha-
tidylinositol 3-kinase (PI3K) –Akt pathway upregulation in resis-
tance.8,18,19 We did not see change by gene expression in PIK3CA or
other pathway members (Akt, mammalian target of rapamycin) in the
11 nonresponders (data not shown); the largest PIK3CA expression
increase was in two patients experiencing SD.
DISCUSSION
This trial, among the largest prospective clinical trials limited to
TNBC, allowed us to examine a therapeutic question, define the sub-
type composition of TNBC, and illustrate the behavior and prognosis
of this phenotype. Findings included a high degree of visceral involve-
ment; 2-month TTP, with several patients experiencing rapid progres-
sion; and OS  1 year. Response to cetuximab alone was uncommon,
and there was low-level activity (RR, 17%) of combination platinum
plus cetuximab.
Many studies in TNBC are based on its overlap with the basal-like
molecular subtype. However, concordance between TNBC on clinical
assays and basal-like gene expression patterns is debated. We found
that basal-like breast cancer comprised approximately 75% of TNBCs;
the remaining 25% represented all other subtypes, including the
claudin-low subtype.12,20 Although a moderately effective enrichment
tool if one is interested in biology of the basal-like subtype, this mo-
lecular heterogeneity must be considered when using triple-negative
clinical assay status as an eligibility criterion.
Both breast cancer type 1 (BRCA1) –associated and sporadic
basal-like breast cancers have characteristics consistent with aber-
rant DNA repair and genome-wide instability,21,22 supporting the
use of DNA-damaging agents such as the platinum in this study.
Clinical data are controversial. Evidence suggests high responsive-
ness to cisplatin in BRCA1-associated breast cancer23; in non-BRCA1
carriers, neoadjuvant cisplatin results in a pathologic CR rate  20%.24
TheexpectedRRtoplatinumagents inunselectedpatientsranges from
10% (pretreated) to 25% (chemotherapy naive).25 Although TNBC may
be more chemosensitive in general,26-28 in a recently reported trial, RR
to cisplatin in first- and second-line treatment of TNBC was only
10%,29 and the pretreated cohort in this study demonstrated an RR of
17%. CALGB 40603 (Cancer and Leukemia Group B; clinicaltrials.gov
identifier NCT00861705), a randomized neoadjuvant study of carbo-
platin added to taxane-based therapy, includes embedded correlative
studies addressing mechanisms of platinum sensitivity and resistance.
In the meantime, existing clinical data do not support preferential use
of platinum agents in sporadic TNBC.
Given the asymptomatic nature of most of the patients in this
study and the short PFS typical in TNBC, both response and























Fig 3. Example of a target lesion biopsied and examined by microarray for epidermal growth factor receptor (EGFR) pathway expression and activation (A) before and
(B) after therapy. Each bubble represents the relative gene expression of a different gene/mRNA in the EGFR pathway (blue, above average expression; dark gold,
average; gold, below average). Across the bottom are three previously defined EGFR activation signatures8 demonstrating activation in the pretherapy specimen and
inactivation after 1 week of combination cetuximab plus chemotherapy. This patient experienced clinical response.
Cetuximab Plus Carboplatin in Triple-Negative Breast Cancer
www.jco.org © 2012 by American Society of Clinical Oncology 2619
remained minorities. Only 31% of patients had disease control for
at least 6 months with combined EGFR inhibitor plus platinum
agent in this study, and PFS for the group as a whole was only 2.1
months, suggesting that the majority without CB had a particularly
aggressive course. One limitation of this study is that it was not
possible to assess the relative contribution of EGFR inhibitor ver-
sus chemotherapy. However, in the randomized phase II trial
BALI-1 (NCT00463788), cetuximab added to cisplatin increased
RR from 10% to 20% and PFS from 1.5 to 3.7 months.29 The TNBC
subset of a randomized study of cetuximab added to irinotecan
plus carboplatin also found improved RR, but no improvement in
PFS or OS was seen; as in this study, a few patients had sustained
long-term responses.16 In fact, the one patient experiencing PFS 
3 years with single-agent cetuximab had a luminal A metastatic
tumor. A broad body of literature implicates EGFR in endocrine
resistance; however, EGFR inhibition in ER-positive breast cancer
without additional selection criteria has similarly had mixed and
generally disappointing results. Although EGFR is a key gene in the
basal-like gene cluster, and EGFR expression is consistent among
basal-like breast cancers, TNBC does not select for EGFR inhibitor
sensitivity. Important lessons can be learned from embedded cor-
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Fig 4. Effect of cetuximab-based therapy on epidermal growth factor receptor (EGFR) pathway expression. (A) Mean expression of the a priori–defined EGFR
activation cluster 28 in 18 patients, including 16 serial biopsy specimens before and after beginning anti-EGFR therapy, demonstrating that most, but not all,
triple-negative breast cancers were basal like, and most had activation of the EGFR pathway (above dashed line). EGFR pathway inhibition was apparent in only a
minority of tumors 7 to 14 days after beginning anti-EGFR therapy. Subtype is designated by shape, whereas colors designate clinical response. Dashed line represents
the cut point for high or “on” EGFR activation signature. (B) Relationship of EGFR expression signature to response before treatment, demonstrating that high EGFR
expression was significantly associated with poor responsiveness to therapy, particularly if EGFR expression remained high after 7 to 14 days of therapy. HER2, human
epidermal growth factor receptor 2; ND, not known; PD, progressive disease; PR, partial response; SD, stable disease.
Carey et al





















































































































Fig 5. Relationship of signatures (measured pretreatment and after 7 to 14 days) known to affect epidermal growth factor receptor signaling on response to
cetuximab-based therapy. Low expression of several signatures measured in pretreatment samples was not associated with response; however, low expression of
the same signatures after 7 to 14 days of treatment was significantly associated with clinical benefit: (A, B) 11-gene proliferation signature, (C, D) distance to claudin-low
centroid (smaller distance indicates more claudin-low like), and (E, F) KRAS amplicon (amp) signature. PD, progressive disease; PR, partial response; SD, stable disease.
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interest and expertise among participating institutions, fewer than
20% of patients underwent serial biopsy. Rational therapeutic
development in the molecular era requires that we improve this
rate. This serial biopsy substudy, which included patients in both
single-agent and combination arms, found that most TNBCs had
EGFR pathway activation, as assessed by a genomic signature.
However, after 1 to 2 weeks of EGFR inhibitor therapy, only a
minority demonstrated pathway inhibition. This suggests that ei-
ther cetuximab is ineffective against this target (unlikely, given
activity in other tumor types) or that there are alternate mecha-
nisms that do not depend on ligand-dependent EGFR-mediated
activation. In this limited sample, we found biologically plausible
candidates such as the EGFR pathway and KRAS amplicon. As was
seen with the preoperative endocrine prognostic index for neoad-
juvant endocrine therapy,30 we also found that tumor biomarkers
may be more informative 1 to 2 weeks after beginning therapy.
Preliminary data from a combined data set of TNBC treated in this
and another study16 suggested that certain molecules, such as
phosphatase and tensin homolog loss and alpha B-crystallin ex-
pression, may affect responsiveness to EGFR inhibitor– based ther-
apy.31 We believe that many TNBCs may be EGFR pathway
dependent, but the constitutive pathway activation in many cases
may not be via EGFR but instead by downstream components such
as KRAS amplification or CRYAB expression. From the clinical and
correlative studies, it is clear that EGFR inhibition alone is unlikely
to provide disease control in most TNBCs; combination strategies
targeting other components of the pathway and dedicated tissue–
based studies are likely to be necessary.
Metastatic TNBC carries a poor prognosis, and treatment is
limited to chemotherapy. This study demonstrated that although
most TNBCs were basal like, a breast cancer subtype characterized
by higher expression of EGFR, there was little activity seen with an
EGFR inhibitor added to a platinum agent. Serial biopsies of the
target tumor in a subset of patients before and after therapy re-
vealed that although most had EGFR expression and pathway
activation, the EGFR inhibitor seldom inactivated this pathway.
Therapy targeting growth factor pathways in this subtype may
require a far better understanding of the pathways maintaining
EGFR activity, molecular inhibitors of the downstream pathways,
and combinatorial strategies. In practical terms, this means that
clinical advances in TNBC are unlikely to be successful unless we
can seamlessly incorporate tissue-based studies in parallel with
clinical trials and do it in 100% of patients.
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